Regeneron Pharmaceuticals Becomes #27 Most Shorted Nasdaq 100 Component, Replacing PACCAR

The most recent short interest data has been released by the NASDAQ for the 01/31/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

In our new rank based on the most recent short interest data from NASDAQ, Regeneron Pharmaceuticals, Inc. ( REGN) has taken over the position of #27 most shorted Nasdaq 100 component, from PACCAR Inc. ( PCAR) which is now in the #30 spot. The "days to cover" at 01/31/2014 was 4.15 for REGN, and 3.71 for PCAR; this compares to the average across all Nasdaq 100 components of 3.68 (down from the average back on the 01/15/2014 settlement date of 4.30). The chart below shows the movement over time of the "days to cover" values of both REGN and PCAR, versus the average Nasdaq 100 component.

Loading+chart++2014+TickerTech.com

Below is a chart showing the relative positions of REGN versus PCAR over time within the 100 Nasdaq 100 components, with #1 representing the component with the highest "days to cover" value (most heavily shorted) and #100 representing the component with the lowest "days to cover" value (least heavily shorted):

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round